DE ANTONELLIS, PASQUALINO
 Distribuzione geografica
Continente #
NA - Nord America 416
EU - Europa 380
AS - Asia 286
AF - Africa 20
SA - Sud America 3
Totale 1.105
Nazione #
US - Stati Uniti d'America 408
IT - Italia 219
SG - Singapore 125
HK - Hong Kong 65
CN - Cina 63
NL - Olanda 39
IE - Irlanda 26
FI - Finlandia 21
FR - Francia 21
CI - Costa d'Avorio 20
DE - Germania 20
VN - Vietnam 18
CA - Canada 8
RU - Federazione Russa 8
PT - Portogallo 6
IN - India 5
SE - Svezia 5
TR - Turchia 4
AM - Armenia 3
ES - Italia 3
GB - Regno Unito 3
IR - Iran 3
MK - Macedonia 3
BR - Brasile 2
PL - Polonia 2
CL - Cile 1
CZ - Repubblica Ceca 1
GR - Grecia 1
LV - Lettonia 1
SI - Slovenia 1
Totale 1.105
Città #
Singapore 112
Naples 84
Hong Kong 65
Santa Clara 44
Chandler 37
Amsterdam 34
Napoli 25
Ashburn 22
Millbury 21
Princeton 20
Nanjing 19
Dong Ket 18
Beijing 15
Boston 10
Des Moines 8
Rende 8
Wilmington 8
Battipaglia 7
Ercolano 7
Nanchang 6
Ottawa 6
Rome 6
Salerno 6
Seattle 6
Formia 5
Giugliano in Campania 5
Caserta 4
Munich 4
Norwalk 4
Rohtak 4
Washington 4
Braga 3
Falls Church 3
Helsinki 3
Jiaxing 3
Los Angeles 3
Nuremberg 3
Portici 3
Prilep 3
Yerevan 3
Campinas 2
Dublin 2
Kish 2
Lawrence 2
Lissone 2
Monfalcone 2
Moscow 2
Padova 2
San Giorgio a Cremano 2
Shanghai 2
Shenyang 2
Abidjan 1
Ann Arbor 1
Bari 1
Berezniki 1
Bologna 1
Bresso 1
Changchun 1
Chicago 1
Dongyang 1
Falkenstein 1
Fara Novarese 1
Fort St. James 1
Genoa 1
Giaveno 1
Giulianova 1
Giussano 1
Gunzenhausen 1
Hebei 1
Izmir 1
Kronberg 1
Lambeth 1
Livorno 1
London 1
Marcianise 1
Marigliano 1
Milan 1
New York 1
Nottingham 1
Orange 1
Piraeus 1
Pomigliano D'arco 1
Pompei 1
Prague 1
Riga 1
San Sebastian 1
Scafati 1
Springfield 1
Sudbury 1
Toronto 1
Warmond 1
Woodbridge 1
Wuhu 1
Totale 715
Nome #
Pyrimido[5,4-d]Pyrimidine or pyrimidine derivates compounds and uses there of in the treatment of cancer 100
Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition. 74
Early targets of miR-34a in neuroblastoma 62
MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines 58
In vivo bioluminescence imaging using orthotopic xenografts towards patient's derived-xenograft Medulloblastoma models 50
Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation 46
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. 44
Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer 40
Cytogenetic Prognostication Within Medulloblastoma Subgroups 38
Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals 37
DDDR-32. A NEW IMMUNOMODULATORY FUNCTION OF PYRIDO-PYRIMIDINE DERIVATIVES TO IMPAIR METASTATIC GROUP 3 MEDULLOBLASTOMA IN VIVO 37
MiR-34a Targeting of Notch Ligand Delta-Like 1 ImpairsCD15+/CD133+ Tumor-Propagating Cells and SupportsNeural Differentiation in 36
The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma. 36
A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction. 36
The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. 35
MiR-34a deficiency accelerates medulloblastoma formation in vivo 35
Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. 30
H-Prune through GSK-3?? interaction sustains canonical WNT/??-catenin signaling enhancing cancer progression in NSCLC. 30
A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases 29
Molecular networks that regulate cancer metastasis. 28
MicroRNAs and Cancer Stem Cells in Medulloblastoma 27
Norcantharidin impairs medulloblastoma growth by inhibition of Wnt/β-catenin signaling. 26
Epigenetics and immune cells in medulloblastoma 21
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. 20
Targeting Group 3 Medulloblastoma by the Anti-PRUNE-1 and Anti-LSD1/KDM1A Epigenetic Molecules 18
Targeting ATP2B1 impairs PI3K/Akt/FOXO signaling and reduces SARS-COV-2 infection and replication 17
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. 17
Failure of human rhombic lip differentiation underlies medulloblastoma formation 16
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma 15
Afatinib, a lung cancer inhibitor of ErbB family 14
null 14
International patent: PCT/EP2023/079960 - WO/2024/089190 - EP4361137; “Prune_1 inhibitors and therapeutic use thereof” 13
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas 10
Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma 9
Gene methylation in liquid biopsy and risk of recurrence in lung cancer 9
Hepatocellular carcinoma: H-Prune gene regulatory networks 8
Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors 8
Patent n. EP22154018: “Antisense compounds for the treatment of coronavirus infection” 7
SARS-CoV-2 uses Spike glycoprotein to control the host's anaerobic metabolism by inhibiting LDHB 7
H-Prune through GSK-3β interaction sustains canonical WNT/β-catenin signaling enhancing cancer progression in NSCLC 6
Erratum: A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases (S0092867418301156 (2018) 172(5) (1050–1062.e14) (S0092867418301156) (10.1016/j.cell.2018.01.038)) 5
Italian Patent: n. 102023000016338; “Composition with antiviral, antibacterial and antifungal activity” 5
Italian Patent: n. 102023000022647; “ELYSIVIR against the PI3K/Akt and TGF beta signaling cascade during SARS-CoV-2 viral infection” 4
Totale 1.177
Categoria #
all - tutte 6.731
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.731


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202025 0 0 0 0 0 0 1 3 1 5 15 0
2020/202131 2 0 0 0 1 0 2 2 2 1 3 18
2021/2022127 1 0 1 3 2 5 3 3 29 10 23 47
2022/2023196 25 5 3 5 31 11 2 12 44 27 22 9
2023/2024250 10 39 63 17 15 9 11 31 3 10 30 12
2024/2025348 56 45 19 27 44 76 81 0 0 0 0 0
Totale 1.177